These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 36825849)

  • 1. Implied Claims in Drug Advertising: A Review of Recent Literature and Regulatory Actions.
    Aikin KJ; Boudewyns V; Betts KR; Giombi KC; Paquin RS; Brewington M; Malik R
    Health Commun; 2024 Apr; 39(4):652-665. PubMed ID: 36825849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Content analysis of false and misleading claims in television advertising for prescription and nonprescription drugs.
    Faerber AE; Kreling DH
    J Gen Intern Med; 2014 Jan; 29(1):110-8. PubMed ID: 24030427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Attorney Advertising and FDA Action with Prescription Claims: A Time Series Segmented Regression Analysis.
    Tippett EC; Chen BK
    Drug Saf; 2015 Dec; 38(12):1169-78. PubMed ID: 26384489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Tip of the Iceberg of Misleading Online Advertising Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
    Mintzes B
    Int J Health Policy Manag; 2016 Feb; 5(5):329-31. PubMed ID: 27239883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of comparative claims in prescription drug direct-to-consumer advertising on consumer perceptions and recall.
    O'Donoghue AC; Williams PA; Sullivan HW; Boudewyns V; Squire C; Willoughby JF
    Soc Sci Med; 2014 Nov; 120():1-11. PubMed ID: 25194471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Legislative/Legal History of Prescription Drug Advertising and Promotion Regulation.
    Li S; Gibbs I
    J Pharm Pharm Sci; 2021; 24():381-389. PubMed ID: 34314671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A scoping review of empirical research on prescription drug promotion.
    Giombi K; Thompson J; Wines C; Haughney R; Sullivan HW; Betts KR
    Res Social Adm Pharm; 2023 Jun; 19(6):859-872. PubMed ID: 36931982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of US Food and Drug Administration Warning Letters: False Promotional Claims Relating to Prescription and Over-the-Counter Medications.
    Salas M; Martin M; Pisu M; McCall E; Zuluaga A; Glasser SP
    Pharmaceut Med; 2008 Mar; 22(2):. PubMed ID: 24353430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health Claims About Cannabidiol Products: A Retrospective Analysis of U.S. Food and Drug Administration Warning Letters from 2015 to 2019.
    Wagoner KG; Lazard AJ; Romero-Sandoval EA; Reboussin BA
    Cannabis Cannabinoid Res; 2021 Dec; 6(6):559-563. PubMed ID: 34142863
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA actions against health economic promotions, 2002-2011.
    Neumann PJ; Bliss SK
    Value Health; 2012; 15(6):948-53. PubMed ID: 22999146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical Marketing in the United States, 1997-2016.
    Schwartz LM; Woloshin S
    JAMA; 2019 Jan; 321(1):80-96. PubMed ID: 30620375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Advertising Violations: A Longitudinal Trend Analysis of FDA Enforcement Letters from 2005 to 2019.
    Zagrodney KAP; Sheikhan NY; Pinto A; Sheikhan T; Witek TJ
    Pharmaceut Med; 2021 Jan; 35(1):31-38. PubMed ID: 33453042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation.
    Stewart KA; Neumann PJ
    Value Health; 2002; 5(5):390-7. PubMed ID: 12201856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fair Balance and Adequate Provision in Direct-to-Consumer Prescription Drug Online Banner Advertisements: A Content Analysis.
    Adams C
    J Med Internet Res; 2016 Feb; 18(2):e33. PubMed ID: 26892749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capsule commentary on Faerber et al., content analysis of false and misleading claims in television advertising for prescription and nonprescription drugs.
    Alexander GC
    J Gen Intern Med; 2014 Jan; 29(1):180. PubMed ID: 24081444
    [No Abstract]   [Full Text] [Related]  

  • 16. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.
    Kim H
    Int J Health Policy Manag; 2015 Aug; 4(12):813-21. PubMed ID: 26673465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality-of-life claims in prescription drug advertisements.
    Rothermich EA; Pathak DS; Smeenk DA
    Am J Health Syst Pharm; 1996 Jul; 53(13):1565-9. PubMed ID: 8809277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correction of misleading information in prescription drug television advertising: The roles of advertisement similarity and time delay.
    Aikin KJ; Southwell BG; Paquin RS; Rupert DJ; O'Donoghue AC; Betts KR; Lee PK
    Res Social Adm Pharm; 2017; 13(2):378-388. PubMed ID: 27178746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of the warning letters issued by the FDA to pharmaceutical manufacturers regarding misleading health outcomes claims.
    Chatterjee S; Patel HK; Sansgiry SS
    Pharm Pract (Granada); 2012 Oct; 10(4):194-8. PubMed ID: 24155837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detecting and Reporting Deceptive Prescription Drug Promotion: Differences Across Consumer and Physician Audiences and by Number and Type of Deceptive Claims and Tactics.
    Betts KR; O'Donoghue AC; Johnson M; Boudewyns V; Paquin RS
    Health Commun; 2022 Nov; 37(13):1609-1621. PubMed ID: 33840305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.